Artemis Diagnostics Announces Company Name Change to Lightpoint Medical, and Appointment of David Ford to the Board of Directors
RICKMANSWORTH, England, January 25, 2013 --
Artemis Diagnostics Ltd, a developer of innovative imaging technologies for cancer surgery, announced today that the company has changed its name to Lightpoint Medical Ltd. The name change reflects the company's focus on the medical device sector.
The company also announced the appointment of David Ford to its Board of Directors. Mr Ford has more than 20 years' experience in the medical device industry including 12 years at board level. Formerly the Executive Director of BSI Group, he was responsible for the worldwide Healthcare and Testing activity for the British Standards Institution. During David's tenure, BSI became the leading certification and accreditation body to the global healthcare industry incorporating two notified bodies in support of the European Medical Devices Directive. David is currently a Non-Executive Director at TrusTECH, an innovation gateway within the NHS. He has represented the United Kingdom at the World Health Organization, the FDA and the European Commission in developing policy for medical devices and medical device regulation. David was trained at St. Mary's Hospital Medical School, London and at Brunel University, and holds an MBA from INSEAD.
Dr David Tuch, CEO of Lightpoint Medical, commented "We are delighted to welcome David Ford to our Board of Directors. David's extensive experience in medical device regulations, marketing, and sales will bring significant value to Lightpoint Medical. We look forward to his contributions to the company as we advance our imaging technology to the market."
About Lightpoint Medical
Lightpoint Medical is an early-stage medical device company seeking to improve health outcomes for cancer patients through image-guided surgery. The company's molecular imaging technology, based on Cerenkov Luminescence Imaging, has the potential to detect cancer in real-time during surgery, providing more accurate cancer treatment while sparing healthy tissue.
For more information contact David Tuch on +44-(0)7725-832-539, email@example.com or visit http://www.lightpointmedical.com.